Disc Medicine, INC Form 4 insider transactions

Jonathan Yen-Wen Yu, Chief Operating Officer of Disc Medicine, Inc., sold 804 shares of common stock on August 12, 2026 for $82.64 per share.

Rahul Khara, Chief Legal Officer of Disc Medicine, Inc., sold 5,000 shares of common stock on August 6, 2026 for $80.00 per share.

John D Quisel, Chief Executive Officer and a Director of Disc Medicine, Inc., sold 33,000 shares of common stock on July 13, 2026.

Disc Medicine COO Jonathan Yu executed trades involving company stock and stock options under a pre-arranged 10b5-1 plan.

Disc Medicine's Chief Legal Officer, Rahul Khara, executed trades involving company stock and stock options under a pre-arranged 10b5-1 plan.

Disc Medicine, Inc. (IRON) reports that Chief Operating Officer Jonathan Yen-Wen Yu executed a Rule 10b5-1 trading plan, involving the acquisition and disposition of company stock.

Disc Medicine COO Jonathan Yen-Wen Yu reports sale of 9,700 common shares and acquisition of 9,700 shares via stock option exercise under a pre-arranged trading plan.

Disc Medicine, Inc. Chief Operating Officer Jonathan Yen-Wen Yu executed a Rule 10b5-1 trading plan, resulting in the sale of company stock and the acquisition of stock options.

Chief Medical Officer William Jacob Savage sold 5,731 shares of Disc Medicine, Inc. common stock via a 10b5-1 trading plan.

Chief Financial Officer Jean M. Franchi sold 6,657 shares of Disc Medicine, Inc. common stock via a Rule 10b5-1 plan.

Disc Medicine's Chief Medical Officer, William Jacob Savage, sold 7,378 shares of common stock on March 2, 2026, through a pre-arranged 10b5-1 trading plan.

Disc Medicine's Chief Financial Officer, Jean M. Franchi, sold 353 shares of common stock for a weighted average price of $69.0569 per share.

Disc Medicine's Chief Financial Officer, Jean M. Franchi, reported sales of common stock, including a 'sell to cover' transaction and sales under a Rule 10b5-1 plan.

Disc Medicine's Chief Legal Officer, Rahul Khara, acquired 17,000 restricted stock units and 25,500 stock options, increasing his beneficial ownership.

Disc Medicine's Chief Commercial Officer, Pamela Stephenson, was granted 17,000 restricted stock units and 25,500 stock options.

Disc Medicine's Chief Medical Officer, William Jacob Savage, was granted 17,000 restricted stock units and options to purchase 25,500 shares of common stock.

Disc Medicine's Chief Operating Officer, Jonathan Yen-Wen Yu, was granted 17,000 restricted stock units and options to purchase 25,500 shares.

Disc Medicine, Inc.'s Chief Financial Officer, Jean M. Franchi, was granted 19,000 restricted stock units and options to purchase 25,500 shares of common stock.

Disc Medicine, Inc. CEO John D. Quisel was granted 55,200 restricted stock units and 82,800 stock options, effective February 10, 2026.

Disc Medicine's Chief Legal Officer, Rahul Khara, exercised stock options and sold 1,000 shares of common stock as part of a pre-arranged 10b5-1 trading plan.

Disc Medicine's Chief Legal Officer, Rahul Khara, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

Disc Medicine's Chief Medical Officer, William Jacob Savage, exercised stock options to acquire common stock.

Disc Medicine, Inc. CEO John D. Quisel exercised stock options to acquire 12,300 shares of common stock at $1.01 per share.

Disc Medicine Director Kevin Bitterman reported the sale of 754 common shares at a weighted average price of $91.47 through affiliated investment funds.

Disc Medicine Director Kevin Bitterman reported the sale of over 182,000 shares of common stock, including an option exercise and subsequent sale, in mid-December 2025.

Disc Medicine's Chief Medical Officer, William Jacob Savage, sold a total of 13,093 shares of common stock on December 15, 2025, under a pre-arranged 10b5-1 trading plan.

Disc Medicine CEO John D. Quisel exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

Disc Medicine's Chief Operating Officer, Jonathan Yen-Wen Yu, exercised stock options and subsequently sold 30,000 shares of common stock for a significant profit.

A 10% owner and director entity sold over 744,000 shares of Disc Medicine common stock in a secondary offering.

A director at Disc Medicine, Kevin Bitterman, reported multiple indirect sales of common stock totaling 93,535 shares across several investment funds.